DB:24H

Stock Analysis Report

Executive Summary

Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Hansa Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 24H's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.7%

24H

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-64.5%

24H

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 24H underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 24H underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

24HIndustryMarket
7 Day8.7%-2.3%-0.2%
30 Day8.6%-3.2%0.3%
90 Day-38.4%6.3%3.7%
1 Year-64.5%-64.5%8.6%8.4%17.2%13.7%
3 Yearn/a44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Hansa Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hansa Biopharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 24H (€7.41) is trading below our estimate of fair value (€40.59)

Significantly Below Fair Value: 24H is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 24H is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 24H is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 24H's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 24H is overvalued based on its PB Ratio (6.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Hansa Biopharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

34.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 24H is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 24H is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 24H is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 24H's revenue (50.3% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 24H's revenue (50.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 24H is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Hansa Biopharma performed over the past 5 years?

-39.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 24H is currently unprofitable.

Growing Profit Margin: 24H is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 24H is unprofitable, and losses have increased over the past 5 years at a rate of -39.6% per year.

Accelerating Growth: Unable to compare 24H's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 24H is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 24H has a negative Return on Equity (-63.97%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Hansa Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: 24H's short term assets (SEK615.7M) exceed its short term liabilities (SEK93.9M).

Long Term Liabilities: 24H's short term assets (SEK615.7M) exceed its long term liabilities (SEK7.6M).


Debt to Equity History and Analysis

Debt Level: 24H's debt to equity ratio (0.1%) is considered satisfactory.

Reducing Debt: 24H's debt to equity ratio has increased from 0% to 0.1% over the past 5 years.


Balance Sheet

Inventory Level: 24H has a low level of unsold assets or inventory.

Debt Coverage by Assets: 24H's debt is covered by short term assets (assets are 843.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 24H has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 24H has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -41.9% each year.


Next Steps

Dividend

What is Hansa Biopharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 24H's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 24H's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 24H's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 24H's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 24H's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Søren Tulstrup (54yo)

1.9yrs

Tenure

0

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Medical AB (publ) since March 20, 2018. Mr. Tulstrup served as the Chief Executive Officer of Vifor Pharma Ltd. since Augus ...


Leadership Team

NamePositionTenureCompensationOwnership
Søren Tulstrup
President & CEO1.9yrsno data0.025% SEK80.3k
Donato Spota
CFO & Senior VP0.8yrsno datano data
Christian Kjellman
CSO & COO0yrsno datano data
Eva-Maria Joed
Vice President of Finance & Administration0.8yrsno data0.022% SEK72.3k
Klaus Sindahl
Head of Investor Relations0yrsno datano data
Rolf Gulliksen
Head of Corporate Communications0yrsno datano data
Anne Lanner
Vice President of Global Human Resources1.1yrsno data0.00090% SEK2.9k
Henk J. van Troostwijk
Senior VP & Chief Commercial Officer0.6yrsno datano data

0.8yrs

Average Tenure

52yo

Average Age

Experienced Management: 24H's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Birgit Norinder
Director8.1yrskr467.00k0.11% SEK338.7k
Ulf Wiinberg
Chairman of the Board1.9yrskr2.56m0.29% SEK917.8k
Anders Pedersen
Director1.8yrskr210.00k0.0063% SEK20.1k
Eva Nilsagård
Director0.8yrsno datano data
Andreas Eggert
Director1.8yrskr204.00k0.014% SEK44.1k
Gunnar Tufveson
Chairman of European Medical Advisory Board in Transplantation0yrsno datano data
Kathryn Wood
Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation0yrsno datano data
Christophe Legendre
Member of European Medical Advisory Board in Transplantation0yrsno datano data
Stanley Jordan
Chairman of US Medical Advisory Board in Transplantation0yrsno datano data
Robert Montgomery
Member of US Medical Advisory Board in Transplantation0yrsno datano data

1.8yrs

Average Tenure

64.5yo

Average Age

Experienced Board: 24H's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 24H insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.4%.


Top Shareholders

Company Information

Hansa Biopharma AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hansa Biopharma AB (publ)
  • Ticker: 24H
  • Exchange: DB
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr3.408b
  • Listing Market Cap: kr321.264m
  • Shares outstanding: 40.03m
  • Website: https://www.hansabiopharma.com

Number of Employees


Location

  • Hansa Biopharma AB (publ)
  • Scheelevägen 22
  • Lund
  • Skåne County
  • 222 63
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HNSAOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKOct 2007
HNSB.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDOct 2007
0RC7LSE (London Stock Exchange)YesClass B SharesGBSEKOct 2007
24HDB (Deutsche Boerse AG)YesClass B SharesDEEUROct 2007
HNSA NBMV (Bolsa Mexicana de Valores)YesClass B SharesMXMXNOct 2007

Biography

Hansa Biopharma AB (publ), a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. The company’s lead drug candidate is Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS), a proprietary antibody-degrading enzyme for kidney transplant patients, as well as for antibody disease and guillain barre syndrome. Its preclinical stage product candidates include Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has collaborative agreement with Axis-Shield Diagnostics Limited to develop Heparin Binding Protein (HBP)-assay, a novel diagnostic method that predicts severe sepsis in patients with infectious disease symptoms. Hansa Biopharma AB (publ) was founded in 2001 and is headquartered in Lund, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 23:27
End of Day Share Price2020/02/20 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.